📇 Rhumatologue · ROUEN CEDEX · (76) · Salarié

MME NATHALIE CONTENTIN

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ROUEN CEDEX (76)SalariéRPPS 10001955540

📊 Reconnaissance scientifique : 28/100📝 109 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Lancet (London, England) · 2012

📚 809 citations🎯 RCR 20.39Top 1% NIH🩺 Clinique

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010

📚 188 citations🎯 RCR 4.59Top 9% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

PurposeIn patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of cytarabine have been reported as being too toxic for patients older than age 50 years, but few studies have evaluated intensified doses of anthracyclines.Patients and MethodsIn this randomized Acute Leukemia French Association 9801 (ALFA-9801) study, high doses of daunorubicin (DNR; 80 mg/m2/d × 3 days) or idarubicin (IDA4; 12 mg/m2/d × 4 days) were compared with standard doses of idarubicin (IDA3; 12 mg/m2/d × 3 days) for remission induction in patients age 50 to 70 years, with an event-free survival (EFS) end point. After two consolidation courses based on intermediate doses of cytarabine, patients in continuous remission were randomly assigned to receive or not receive maintenance therapy with recombinant interleukin-2 (rIL-2; 5 × 106U/m2× 5 days each month) for a total duration of 12 months. A total of 468 patients entered the study (median age, 60 years).ResultsOverall complete remission rate was 77% with significant differences among the three randomization arms (83%, 78%, and 70% in the IDA3, IDA4, and DNR arms, respectively; P = .04). However, no significant differences were observed in relapse incidence, EFS, or overall survival among the three arms. In the 161 patients randomly assigned for maintenance therapy, no difference in outcome was observed between the rIL-2 and the no further treatment arms.ConclusionNeither intensification of anthracycline doses nor maintenance with rIL-2 showed a significant impact on AML course, at least as scheduled in this trial.

Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy

European journal of haematology · 2014

📚 117 citations🎯 RCR 4.27Top 10% NIH

Lire l'abstract Crossref ↓

AbstractObjectivesApproximately 30% of DLBCL patients are older than 70 yr. This study evaluated the prognostic impact of a cachexia score (CS) including fat tissue loss (adipopenia) and sarcopenia as assessed by computed tomography (CT scan) in elderly DLBCL patients treated with chemotherapy and rituximab (R).MethodsThis retrospective analysis included 80 DLBCL patients older than 70 yr treated with R‐CHOP or R‐miniCHOP. Skeletal muscle (SM) and visceral (V) and subcutaneous (S) adipose (A) tissues were measured by analysing CT images at the third lumbar (L3) level.ResultsThe median age of the patients was 78 yr. Forty‐four and 46 patients were considered sarcopenic and adipopenic, respectively. The median progression‐free survival (PFS) was 13.6 months in the adipopenic group and 49.4 months in the non‐adipopenic group [hazard ratio (HR) = 2.27; 95% confidence interval (CI): 1.3–4; P = 0.0042]. The median overall survival (OS) was 25.7 months in the adipopenic group and 57.1 months in the non‐adipopenic group (HR = 1.93; 95% CI: 1.05–3.55; P = 0.0342). A two‐point CS including adipopenia and sarcopenia was created and defined two distinct risk groups with differences in outcomes that were highly significant. The CS was predictive of the prognosis in a multivariate analysis including body mass index (BMI) (< or ≥25 kg/m2), age (< or ≥80 yr), international prognostic index (IPI) and albuminaemia (HR = 3.67; 95% CI = 1.93–6.97; P < 0.0001).ConclusionA CS including sarcopenia and adipopenia, assessed by a single CT scan slice, predicts outcome independent of BMI and the IPI.

Cookies & analyse de trafic

MME NATHALIE CONTENTIN

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Transversal13

Case report / série3

Épidémiologie & registres3

Essai clinique3

Gériatrie3

Génétique1

Pédiatrie1

Pharmacovigilance1

Vraie vie / RWE1

Partager cette fiche